Hepion Pharmaceuticals’ Strategic Merger and Corporate Restructuring

An update from Hepion Pharmaceuticals (HEPA) is now available.

Hepion Pharmaceuticals has entered into a merger agreement with Pharma Two B Ltd. and Pearl Merger Sub, Inc., which will result in Hepion becoming an indirect wholly owned subsidiary of Pharma Two B Ltd. The deal, subject to conditions and approvals, will see Hepion’s stock converted into shares of the parent company. The merger is expected to close in the fourth quarter of 2024, with the combined entity’s shares to be listed on Nasdaq. Additionally, the agreement includes a no-shop provision, termination fees, and pre-merger restructuring of capital stock.

See more data about HEPA stock on TipRanks’ Stock Analysis page.